Clinical Trial Update: A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of ZW25 (zanidatamab) with palbociclib and fulvestrant in HER2+/HR+ advanced breast cancer completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Palbociclib (palbociclib)
• ZW25 (zanidatamab)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: HER2+/HR+ Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-08-14